FDA Clearance Tracker · P130008
INSPIRE II UPPER AIRWAY STIMULATOR
Last checked: Nov 19, 2026Latest source record: Apr 30, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Apr 30, 2014
Approved
Time to decision
364 days
Received May 1, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P130008
- Device name
- INSPIRE II UPPER AIRWAY STIMULATOR
- Applicant
- Inspire Medical Systems
- Applicant location
- Maple Grove, MN
- Received
- May 1, 2013
- Decided
- Apr 30, 2014
- Decision
- Approved
- Supplements
- 138 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE INSPIRE UPPER AIRWAY STIMULATION (UAS) SYSTEM, WHICH INCLUDES THE MODEL 3024 IMPLANTABLE PULSE GENERATOR, THE MODEL 4063 STIMULATION LEAD, THE MODEL 4323 SENSING LEAD, THE MODEL 2740PHYSICIAN PROGRAMMER, AND THE MODEL 3032 PATIENT PROGRAMMER. THE DEVICE IS USED TO TREAT A SUBSET OF PATIENTS WITH MODERATE TO SEVERE OBSTRUCTIVE SLEEP APNEA (OSA) (APNEA-HYPOPNEA INDEX [AHI] OF GREATER OR EQUAL TO 20 AND LESS THAN OR EQUAL TO 65). INSPIRE UAS IS USED IN ADULT PATIENTS 22 YEARS OF AGE AND OLDER WHO HAVE BEEN CONFIRMED TO FAIL OR CANNOT TOLERATE POSITIVE AIRWAY PRESSURE (PAP) TREATMENTS (SUCH AS CONTINUOUS POSITIVE AIRWAY PRESSURE [CPAP] OR BILEVEL POSITIVE AIRWAY PRESSURE [BPAP] MACHINES) AND WHO DO NOT HAVE A COMPLETE CONCENTRIC COLLAPSE AT THE SOFT PALATE LEVEL. PAP FAILURE IS DEFINED AS AN INABILITY TO ELIMINATE OSA (AHI OF GREATER THAN 20 DESPITE PAP USAGE) AND PAP INTOLERANCE IS DEFINED AS: 1) INABILITY TO USE PAP (GREATER THAN 5 NIGHTS PER WEEK OF USAGE; USAGE DEFINED AS GREATER THAN 4 HOURS OF USE PER NIGHT); OR 2) UNWILLINGNESS TO USE PAP (FOR EXAMPLE, A PATIENT RETURNS THE PAP SYSTEM AFTER ATTEMPTING TO USE IT).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MNQ (Stimulator, hypoglossal nerve, implanted, apnea).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Inspire Medical Systems
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Inspire Upper Airway Stimulation SystemPMA supplement
P130008-S090 · Decided Jun 8, 2023 · 234 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
- Inspire Upper Airway StimulationPMA supplement
P130008-S089 · Decided Mar 20, 2023 · 213 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
- Inspire Upper Airway StimulationPMA supplement
P130008-S039 · Decided Apr 14, 2020 · 447 days after receipt · Panel Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.